Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wolfdog2 who wrote (1482)	10/30/1998 7:46:00 AM
From: crysball	Read Replies (3) of 1491

NBC News this morning expanded the definintion of at 'high' risk candidates for Breast Cancer population to 29 million US women, including those who have never had children, those who had children late in life, etc. If bringing to the attention of this message board, the size of a rapidly developing (and previously unserved) market, which Pharmos has a Tamoxifen analogue for and which purportedly addresses the sideffect issue of Tamoxifen is considered being 'overexcited', then I am guilty. If nothing else it demonstrates the foresight of management to choose the 'riight stuff' for the pipeline. . For years women have had no options, except to await with trepadation the outcome of their annual mammography exam [assuming their healh plan provides this option], now those women at high risk of breast cancer can take some action to gian control over their destiny AND REDUCE THEIR RISK........this of course has to balanced against the sideeffects of the currently available form of Tamoxifen (note PARS analogue Tamoxifen Methiodide is alleged to mitiagate these sideeffects). As NBC News pointed out Women's clnics are already being swamped with calls already.......

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next